View ValuationTegoScience 将来の成長Future 基準チェック /06現在、 TegoScienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長38.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 17TegoScience Inc., Annual General Meeting, Mar 27, 2026TegoScience Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South Korea分析記事 • Jan 28Is TegoScience (KOSDAQ:191420) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Nov 27New major risk - Revenue and earnings growthEarnings have declined by 9.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.2b revenue, or US$4.2m). Market cap is less than US$100m (₩128.1b market cap, or US$87.6m).分析記事 • Sep 01Is TegoScience (KOSDAQ:191420) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Jul 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.2b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₩6.8b revenue, or US$5.0m). Market cap is less than US$100m (₩135.2b market cap, or US$98.9m).お知らせ • May 29TegoScience Inc. announced that it has received KRW 27 billion in fundingOn May 27, 2025, TegoScience Inc. closed the transaction.New Risk • May 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Revenue is less than US$5m (₩6.8b revenue, or US$4.9m).Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩17,950, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 5.3% over the past three years.分析記事 • Mar 28We Think That There Are Some Issues For TegoScience (KOSDAQ:191420) Beyond Its Promising EarningsTegoScience Inc.'s ( KOSDAQ:191420 ) robust recent earnings didn't do much to move the stock. We believe that...お知らせ • Mar 07TegoScience Inc., Annual General Meeting, Mar 28, 2025TegoScience Inc., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South KoreaNew Risk • Jan 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₩6.9b revenue, or US$4.7m). Market cap is less than US$100m (₩135.7b market cap, or US$93.0m).Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩14,720, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 30% over the past three years.New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩120.9b market cap, or US$84.1m).Valuation Update With 7 Day Price Move • Dec 02Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩12,360, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past three years.New Risk • Nov 06New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩7.0b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (₩7.0b revenue, or US$5.0m). Market cap is less than US$100m (₩137.6b market cap, or US$98.1m).Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩17,300, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 29% over the past three years.Valuation Update With 7 Day Price Move • Aug 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩16,000, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 43% over the past three years.New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩122.1b (US$89.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₩122.1b market cap, or US$89.5m).New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.6b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩137.6b market cap, or US$99.7m).New Risk • Mar 22New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.06% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).New Risk • Nov 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩81.3b market cap, or US$61.3m).Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₩13,450, the stock trades at a trailing P/E ratio of 79.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 40% over the past three years.Is New 90 Day High Low • Feb 23New 90-day low: ₩26,100The company is down 2.0% from its price of ₩26,700 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.分析記事 • Feb 16Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?TegoScience (KOSDAQ:191420) has had a rough month with its share price down 6.9%. It seems that the market might have...分析記事 • Jan 12How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?A look at the shareholders of TegoScience Inc. ( KOSDAQ:191420 ) can tell us which group is most powerful. Institutions...Is New 90 Day High Low • Dec 22New 90-day high: ₩30,650The company is up 6.0% from its price of ₩28,850 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 14% over the same period.分析記事 • Dec 08Did You Miss TegoScience's (KOSDAQ:191420) Impressive 137% Share Price Gain?When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...Is New 90 Day High Low • Oct 15New 90-day low: ₩26,050The company is down 20% from its price of ₩32,600 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、TegoScience は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A191420 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20255,941-7,012-3,567-3,067N/A9/30/20256,154-3,249-3,036-2,848N/A6/30/20256,516-1,889-2,035-1,934N/A3/31/20256,7983,349-1,933-1,743N/A12/31/20246,7593,350-1,483-1,160N/A9/30/20246,9273,652-753-360N/A6/30/20246,9743,352-1,537-696N/A3/31/20247,194-2,659-1,226-458N/A12/31/20237,772-2,323-2,685-795N/A9/30/20238,016-1,404-2,504-598N/A6/30/20238,134-1,301-1,987-265N/A3/31/20238,202235-772907N/A12/31/20227,6782656051,040N/A9/30/20228,4261,3498711,185N/A6/30/20228,3411,2541,2091,288N/A3/31/20228,162432-131-39N/A12/31/20218,300139234457N/A9/30/20217,573-479388620N/A6/30/20218,23571513787N/A3/31/20218,4559931,2731,578N/A12/31/20208,7891,8319821,280N/A9/30/20208,3231,7618141,164N/A6/30/20207,5801,3389931,228N/A3/31/20206,9831,27376348N/A12/31/20196,346856-9341N/A9/30/20196,723-2,058N/A381N/A6/30/20196,849-2,142N/A269N/A3/31/20197,366-776N/A682N/A12/31/20187,850-1,826N/A834N/A9/30/20188,042-3,071N/A1,967N/A6/30/20188,245-2,888N/A2,051N/A3/31/20188,331-7,515N/A1,802N/A12/31/20178,642-6,021N/A2,865N/A9/30/20178,568-2,985N/A1,495N/A6/30/20178,568-2,610N/A2,035N/A3/31/20178,549776N/A2,720N/A12/31/20168,343772N/A2,357N/A9/30/20168,0491,842N/A2,657N/A6/30/20167,9811,841N/A2,882N/A12/31/20157,4921,473N/A2,633N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A191420の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A191420の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A191420の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A191420の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A191420の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A191420の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 20:53終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TegoScience Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Seung-Ho LeeNH Investment & Securities Co., Ltd.
お知らせ • Mar 17TegoScience Inc., Annual General Meeting, Mar 27, 2026TegoScience Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South Korea
分析記事 • Jan 28Is TegoScience (KOSDAQ:191420) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Nov 27New major risk - Revenue and earnings growthEarnings have declined by 9.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.2b revenue, or US$4.2m). Market cap is less than US$100m (₩128.1b market cap, or US$87.6m).
分析記事 • Sep 01Is TegoScience (KOSDAQ:191420) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Jul 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.2b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₩6.8b revenue, or US$5.0m). Market cap is less than US$100m (₩135.2b market cap, or US$98.9m).
お知らせ • May 29TegoScience Inc. announced that it has received KRW 27 billion in fundingOn May 27, 2025, TegoScience Inc. closed the transaction.
New Risk • May 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Revenue is less than US$5m (₩6.8b revenue, or US$4.9m).
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩17,950, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 5.3% over the past three years.
分析記事 • Mar 28We Think That There Are Some Issues For TegoScience (KOSDAQ:191420) Beyond Its Promising EarningsTegoScience Inc.'s ( KOSDAQ:191420 ) robust recent earnings didn't do much to move the stock. We believe that...
お知らせ • Mar 07TegoScience Inc., Annual General Meeting, Mar 28, 2025TegoScience Inc., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South Korea
New Risk • Jan 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₩6.9b revenue, or US$4.7m). Market cap is less than US$100m (₩135.7b market cap, or US$93.0m).
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩14,720, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 30% over the past three years.
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩120.9b market cap, or US$84.1m).
Valuation Update With 7 Day Price Move • Dec 02Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩12,360, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past three years.
New Risk • Nov 06New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩7.0b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (₩7.0b revenue, or US$5.0m). Market cap is less than US$100m (₩137.6b market cap, or US$98.1m).
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩17,300, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 29% over the past three years.
Valuation Update With 7 Day Price Move • Aug 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩16,000, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 43% over the past three years.
New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩122.1b (US$89.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₩122.1b market cap, or US$89.5m).
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.6b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩137.6b market cap, or US$99.7m).
New Risk • Mar 22New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.06% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
New Risk • Nov 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩81.3b market cap, or US$61.3m).
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₩13,450, the stock trades at a trailing P/E ratio of 79.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 40% over the past three years.
Is New 90 Day High Low • Feb 23New 90-day low: ₩26,100The company is down 2.0% from its price of ₩26,700 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
分析記事 • Feb 16Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?TegoScience (KOSDAQ:191420) has had a rough month with its share price down 6.9%. It seems that the market might have...
分析記事 • Jan 12How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?A look at the shareholders of TegoScience Inc. ( KOSDAQ:191420 ) can tell us which group is most powerful. Institutions...
Is New 90 Day High Low • Dec 22New 90-day high: ₩30,650The company is up 6.0% from its price of ₩28,850 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 14% over the same period.
分析記事 • Dec 08Did You Miss TegoScience's (KOSDAQ:191420) Impressive 137% Share Price Gain?When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Is New 90 Day High Low • Oct 15New 90-day low: ₩26,050The company is down 20% from its price of ₩32,600 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.